documented protocols
Mecasermin: what is documented about dosing
This is a prescription medicine whose dosing is set out in an approved label and used alongside monitoring. The figures are not reproduced here.
- Primary sources Registry records and papers are read at the source, not through summaries. Read the methodology
- Every claim graded Each claim about what a compound does carries an evidence tier and a numbered citation. How grades derive
- Sells nothing No cart, no price, and no product page anywhere on this site. Conflict disclosure
- Corrections logged Errors are fixed and recorded in a permanent public log, never edited away. Corrections log
The dosing for this compound is established, which is unusual on this site. It is also prescribing information, and that is why what follows does not restate it.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
What this page reports, and what it does not
We report what has been documented. We do not prescribe what should be done.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
No trial established an amount of Mecasermin for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.
Commonly cited protocols (extrapolated, not validated)
| Study | What was given | Frequency | Duration | Notes |
|---|---|---|---|---|
| Approved label, BLA021839 | Established and set out in the prescribing information | Set out in the prescribing information | Set out in the prescribing information | Not reproduced on this site. It is a prescription medicine used with monitoring, and restating a label turns a record into guidance |
| The registered trials | As specified by each protocol | As specified by each protocol | Up to long-term in the growth hormone insensitivity study | 29 records. This site did not check whether any has posted results |
| IGF-1 LR3, the analog | Nothing documented | Nothing documented | Nothing documented | A different molecule with no registered trial. Figures do not transfer in either direction |
Commonly cited protocols (extrapolated, not validated) for this molecule are rare, because it is a prescription medicine rather than something sold as a research chemical. Where such figures circulate they are generally attached to the analog instead.
The reason this page withholds the label figures is not that they are unavailable. It is that they come with monitoring, and a number lifted out of a prescribing document and put on a reference page has lost the thing that made it usable.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
Our takeThe figures exist and they belong in a prescribing document with the monitoring that goes alongside them.,Talk to a licensed clinician about anything concerning your health.
Main routes people compare
Subcutaneous injection
The route in the approved label and throughout the registered programme.
What is said about cycle length and timing
Treatment in the approved population is long term rather than cyclical, and its duration is a clinical decision set out in the prescribing information. No cycle length is stated here.
Talk to a licensed clinician about anything concerning your health.
What has been measured about safety
A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about Mecasermin, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.
Frequently asked questions
Is there an established dose for mecasermin?
Yes, in the approved label for the licensed indication. This site does not reproduce it, because it is prescribing information used alongside monitoring.
Why not just publish the label dosing?
A figure taken out of a prescribing document and put on a reference page has lost the monitoring that made it usable. Reproducing it would turn a record into guidance, which this site does not give.
Do these figures apply to IGF-1 LR3?
No. That is a different molecule, engineered to behave differently in circulation, with no registered trial of its own.
References
- US Food and Drug Administration. INCRELEX (mecasermin) injection prescribing information. Biologics licence application BLA021839, Ipsen Biopharmaceuticals, Inc., subcutaneous route. Read through the openFDA drug label API on 23 August 2026. Carries the approved indication and the limitation of use quoted on this page. The label document itself was not read, which is recorded as an open item. openFDA drug label. 2026. Increlex label
- Ipsen. Prepubertal Children With Growth Failure Associated With IGF-1 Deficiency. Phase 3, 137 participants, completed. Read through the ClinicalTrials.gov v2 API on 23 August 2026. ClinicalTrials.gov. 2005. NCT00125164
- Ipsen. Long-Term Treatment With rhIGF-1 in Growth Hormone Insensitivity Syndrome. Phase 2/3, 92 participants, completed. ClinicalTrials.gov. 2007. NCT00571727
- Massachusetts General Hospital. IGF-1 and Bone Loss in Women With Anorexia Nervosa, 148 participants, completed; and Effects of Anorexia Nervosa on Peak Bone Mass, Phase 3, 75 participants, completed. Investigator-led work outside the licensed indication. Registry records read; no publication was read. ClinicalTrials.gov. 2011. NCT01406444
- Ipsen. IGFD Registry: A Patient Registry for Monitoring the approved population after licensing. 1,378 participants, terminated. ClinicalTrials.gov. 2008. NCT00747604
- Esteve Pharmaceuticals. Global Patient Registry to Monitor Long-term Safety. 500 participants, recruiting as of 23 August 2026. ClinicalTrials.gov. 2009. NCT00903110
- ClinicalTrials.gov. Registry sweep for mecasermin, Increlex, mecasermin rinfabate, iPlex, rhIGF-1, IGF-1 LR3 and Long R3 IGF-1, run through the v2 API on 23 August 2026 and filtered to records whose interventions name one of those drugs. Twenty-nine records survive the filter. An unfiltered query returns 135, because IGF-1 is a widely measured biomarker. ClinicalTrials.gov. 2026. ClinicalTrials.gov
- World Anti-Doping Agency. The 2026 Prohibited List. Section S2.3, Growth Factors and Growth Factor Modulators, carries the entry: Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues. The S2 class heading states that the class is prohibited at all times, in and out of competition, and that all substances in it are non-Specified. Read in full on 23 August 2026. World Anti-Doping Agency. 2026. WADA 2026 Prohibited List
- White A, Stremming J, Wesolowski SR, Al-Juboori SI, Dobrinskikh E, Limesand SW, Brown LD, Rozance PJ. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab. 2025. PMID 39679943 DOI 10.1152/ajpendo.00259.2024 Cited here for its description of the analog's engineering, which is what separates that molecule from this one.
- Stremming J, White A, Donthi A, Batt DG, Hetrick B, Chang EI, Wesolowski SR, Seefeldt MB, McCurdy CE, Rozance PJ, Brown LD. Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep. Front Physiol. 2022. PMID 36091374 Cited for what unmodified IGF-1 does in the preparation the analog was also tested in.